Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesGenetic & Molecular TestingBlue Cross Blue Shield RI Biomarker Testing Covera…
    Ask Trek AI about this page
    DraftBlue Cross Blue Shield - Rhode IslandPolicy N/A

    Biomarker Testing / Genetic & Molecular Testing Coverage Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts

    Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs state-mandated coverage, medical necessity, and prior authorization requirements for biomarker and genetic/molecular tests for BCBSRI Commercial Products and Medicare Advantage Plans.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyBiomarker Testing / Genetic & Molecular Testing Coverage Criteria
    Policy CodePolicy N/A
    Change TypeMinor / non‑material revision
    Effective Date08/01/2026
    Last ReviewApr 15, 2026
    Next Review Date04/15/2026
    Key ActionSubmit prior authorization requests via the BCBSRI online prior authorization tool (or fax to Utilization Management for non‑participating providers).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3primary genetic testing categories
    08/01/2026effective date
    Prior auth requiredpanel prior auth
    Extensive gridscoding grids referenced
    65+references cited

    Coverage Criteria and Medical Necessity

    Carrier screening criteria

    Covered when criteria are met as specified below; InterQual/online authorization tool criteria often used.

    Carrier screening (preconception or prenatal): Covered when ALL of the following are met: One or both individuals have a first- or second-degree relative who is affected; one individual is a known carrier; one or both individuals are members of a population with an elevated carrier rate appropriate for testing; AND previous carrier screening or targeted testing for the gene variant(s) of interest has not been performed.N/A

    First-degree relatives include biological parent, brother, sister, or child; second-degree relatives include grandparent, aunt/uncle, niece/nephew, grandchild, and half-sibling.

    Genetic/hereditary testing criteria

    Genetic screening/testing for hereditary conditions when germline testing will benefit the individual:

    Hereditary/genetic testing: Covered when ANY of the following are met: to confirm a suspected diagnosis in a symptomatic patient; to identify a causative etiology for a clinical syndrome with multiple possible underlying conditions; or testing an asymptomatic individual to determine future risk of disease.N/A

    Germline testing must be likely to benefit the individual by informing diagnosis, prognosis, or management.

    Cancer-related testing

    Genetic testing for cancer:

    Cancer genetic testing: Covered when ANY of the following are met: testing an asymptomatic patient to determine future risk of cancer; or therapeutic testing of cancer cells from an affected individual to direct targeted treatment based on specific somatic variants.N/A

    Panel tests represented by multiple CPTs require per-component authorization; panels lacking evidence for individual genes may render the entire panel not covered for Medicare Advantage and not medically necessary for Commercial Products.

    Panel testing policy

    Panel testing coverage stance:

    Panel testing evidence requirement: If there is insufficient evidence that a gene or variant within a genetic panel is useful for guiding patient management and improving net health outcomes, then the entire genetic panel is considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products.N/A

    For panels filed with specific individual CPT codes, refer to the Coding section; panel composition is variable and determined by the testing laboratory.

    General medical necessity

    Coverage depends on clinical validity and clinical utility specific to the condition and test context.

    General coverage considerations: Panel tests and other genetic tests may be covered when analytical validity, clinical validity of underlying variants, and clinical utility in the specific clinical context are established and when expected benefits outweigh potential harms from uncertain findings.context-specific

    Evidence of analytical and clinical validity and demonstrated clinical utility is required; panel composition and clinical relevance vary by laboratory and over time.

    Not medically necessary

    Not medically necessary criteria:

    Insufficient evidence: Tests with extremely limited published data or insufficient evidence demonstrating clinical validity or clinical utility are considered not medically necessary.insufficient evidence

    Such tests are excluded from coverage until evidence supports clinical validity and utility; whole panels may be NMN if individual components lack evidence.

    Some genetic testing services may be contractually excluded for self-funded groups that have chosen to exclude the expanded coverage of biomarker testing under R.I.G.L. §27-19-81. Providers should review the member's Benefit Booklet for plan-specific exclusions and refer to the Coding section and related policies to determine whether a requested test is covered, not medically necessary, or excluded for that member.

    A genetic panel is defined as a test that simultaneously evaluates multiple genes (for example, via NGS, massive parallel sequencing, or chromosomal microarray). The policy expressly excludes panels that report on gene expression profiling, since those assays generally do not directly evaluate genetic variants.

    Services determined to be not medically necessary or services that are medically necessary but are non‑covered benefits (for example, due to a plan's contractual exclusions) are excluded from coverage. Benefits and eligibility are governed by the member's subscriber agreement or employer agreement, which supersede this policy; providers should contact the provider call center or review the member's Benefit Booklet for member‑specific determinations.

    Testing is considered not medically necessary when there is insufficient published evidence or strength of recommendation, when results would not reasonably be used in patient management, or when findings are unlikely to affect therapeutic decision‑making. In particular, panels or tests lacking adequate evidence of clinical validity or utility are excluded until sufficient evidence demonstrates they change management or improve health outcomes.

    When a genetic panel contains one or more genes or variants for which evidence is insufficient to guide clinical management, the policy states that the entire genetic panel may be considered not covered for Medicare Advantage and not medically necessary for Commercial Products. Tests with extremely limited published data or insufficient clinical validity are considered not medically necessary.

    If a service is determined to be not medically necessary or is a non‑covered benefit, laboratories and providers must follow authorization requirements. Per policy, if a laboratory provides a service that was not authorized, the service will be denied as the financial liability of the participating laboratory and may not be billed to the member. Providers may not charge members for non‑covered services unless the member was informed and provided written agreement in advance.

    Covered Indications and Use Cases

    Diagnosis, treatment, appropriate management, or ongoing monitoring when test provides clinical utility

    Covered when the test result provides clinical utility as defined by statute and this policy and directly informs diagnosis, treatment, appropriate management, or ongoing monitoring.

    Clinical utility requirement: Covered when test results are used to establish a diagnosis, to guide treatment selection, to determine appropriate disease management, or for ongoing monitoring when such use is supported by clinical evidence and applicable guidelines.meets statutory definition of clinical utility

    Refer to online authorization tool or attached coding grids for test- and indication-specific criteria.

    Carrier screening covered conditions

    Carrier screening is covered under the following circumstance sets when ALL criteria below are met:

    Family history: One or both individuals have a first- or second-degree relative who is affected by the condition of interest.

    Member and Test Eligibility Requirements

    Eligibility for carrier screening requires that one or more of the following be met: a first‑ or second‑degree relative is affected by the condition; one individual is a known carrier; or one or both individuals belong to a population with an elevated carrier rate appropriate for testing. Additionally, previous carrier screening or targeted testing for the specific gene/variant must not have been performed.

    Carrier testing may be offered to individuals who have family members with a genetic condition, family members identified as carriers, or who are members of ethnic or racial groups with a higher carrier rate for a particular condition. First‑degree relatives include biological parent, sibling, or child; second‑degree relatives include grandparent, aunt/uncle, niece/nephew, grandchild, and half‑sibling.

    More generally, eligibility for genetic testing is established when testing will provide clinical utility to the individual — for diagnosis, to clarify a clinical syndrome, to determine hereditary cancer risk, or to guide treatment and monitoring — and when analytical and clinical validity and clinical utility are supported by evidence or authoritative guidance.

    Coding, CPT/HCPCS/PLA and Coverage Grids

    Proprietary Laboratory Analyses (PLA)mixed
    PLA codesProprietary Laboratory Analyses codes for proprietary clinical laboratory tests (PLA/ADLT/CDLT) when available; PLA takes precedence over other CPT codes for the same service.
    Molecular/GSP codesCPT
    Molecular pathology and GSP/NGS codesCPT codes based on specific gene(s) analyzed and genomic sequencing procedures (GSPs)/NGS methods; code selection typical for molecular pathology and genomic sequencing.
    Coding grids referencedmixed
    See attached gridsMedicare Advantage and Commercial Products coverage grids for biomarker testing codes (MAAA, PLA, pathology/laboratory codes).
    Topic-specific HCPCS/PLA groupingsHCPCS
    Topic-specific HCPCS/PLA groupingsMultiple topic headings listed (e.g., circulating tumor DNA, gene expression profiling, whole exome/genome sequencing, next generation sequencing for solid tumors, multianalyte assays with algorithmic analyses, liquid biopsy, multicancer early detection testing, and many other topic-specific lists) — see attached grids for specific codes.
    Carrier screening population threshold
    Population thresholdOne or both individuals are members of a population known to have a carrier rate that exceeds a threshold considered appropriate for testing for the particular condition.
    Family historyOne or both individuals have a first- or second-degree relative who is affected (first-degree = parent, sibling, child; second-degree = grandparent, aunt/uncle, niece/nephew, grandchild, half‑sibling).
    Known carrierCovered when one individual is a known carrier for the condition being screened.
    Prior testingPrevious carrier screening or targeted gene testing for the variant(s) of interest must not have been performed for coverage to be considered.
    Clinical utility threshold note

    Provider Actions, Prior Authorization, and Billing Guidance

    Prior Authorization

    Prior Authorization Requirements

    Prior authorization review may be required for Medicare Advantage Plans and recommended for Commercial Products in accordance with the Biomarker Testing Mandate. For services with prior authorization indicated in the attached code grids, prior authorization is required for Medicare Advantage Plans and recommended for Fully‑Funded Commercial Products unless an exemption below applies.

    • For Medicare Advantage Plans: prior authorization is required when indicated on the attached coding grids.
    • For Commercial Products: prior authorization is recommended; Fully‑Funded Commercial Products have a PCP exemption effective 2025-10-01 (see PCP exemption callout).
    • Panel testing: when a panel is represented by multiple CPT codes, prior authorization is required for each CPT code — enter each CPT individually in the online authorization tool.

    Not Covered and Excluded Tests

    When individual genes or variants within a panel lack sufficient evidence of clinical utility, the policy treats entire genetic panels as not covered for Medicare Advantage and not medically necessary for Commercial Products. For Medicare Advantage coverage determinations and commercial product medical necessity, providers must assess whether individual gene testing (rather than a broad panel) is appropriate given the available evidence.

    Tests that lack demonstrated clinical utility or have insufficient evidence of clinical validity are considered not medically necessary. The policy cites examples where very limited published data preclude determination of an effect on health outcomes, and thus such tests are excluded from coverage until evidence supports clinical validity and utility.

    Definitions

    Biomarker
    DefinitionA characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention (examples include gene mutations or protein expression).
    Specimen typesBiomarkers may be measured in tissue, blood, or other biospecimens.
    Use casesUsed to indicate disease processes or response to therapy and can inform diagnostic or therapeutic decisions when clinically validated.
    Biomarker testing
    DefinitionAnalysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker, including single-analyte tests, multi-plex panel tests, and whole genome sequencing.
    Included test typesIncludes single-analyte tests, multiplex panel tests, and whole genome sequencing as examples of biomarker testing modalities.

    Background

    Biomarker testing encompasses analysis of tissue, blood, or other biospecimens for biomarkers (for example, gene mutations or protein expression) and includes single‑analyte tests, multiplex panels, genomic sequencing procedures (GSPs/NGS), chromosomal microarray, whole exome/genome sequencing, circulating tumor DNA assays, proprietary laboratory analyses (PLA), and multianalyte assays with algorithmic analyses (MAAA). Panel composition is variable and determined by the laboratory; panels do not include gene expression profiling under this policy.

    Revision History and Policy Updates

    2026-08-01Effective dateLatest

    Policy effective date updated to 2026-08-01.

    2026-04-15Last review

    Clinical policy last reviewed on 2026-04-15.

    2025-10-01Prior authorization change
    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyBiomarker Testing / Genetic & Molecular Testing Coverage Criteria
    Policy CodePolicy N/A
    Change TypeMinor / non‑material revision
    Effective Date08/01/2026
    Last ReviewApr 15, 2026
    Next Review Date04/15/2026
    Key ActionSubmit prior authorization requests via the BCBSRI online prior authorization tool (or fax to Utilization Management for non‑participating providers).
    SourceLink
    On This Page
    Coverage Criteria and Medical NecessityCovered Indications and Use CasesMember and Test Eligibility RequirementsCoding, CPT/HCPCS/PLA and Coverage GridsProvider Actions, Prior Authorization, and Billing GuidanceNot Covered and Excluded TestsDefinitionsBackgroundRevision History and Policy Updates
    N/A

    First- and second-degree relationships defined in policy.

    Known carrier or population risk: Either one individual is a known carrier OR one or both individuals belong to a population with an elevated carrier rate appropriate for testing.population carrier rate exceeds testing threshold

    Population risk thresholds are condition-specific; refer to guidance in authorization tool.

    No prior testing: Previous carrier screening or individual targeted gene testing for the variant(s) of interest has not been performed.N/A

    Prior testing for the specific variants would preclude coverage of repeat testing for the same targets.

    Covered uses

    Covered uses include tests that provide actionable clinical information in the contexts below:

    Diagnosis of hereditary disorders: Testing to confirm or establish a hereditary diagnosis when results will influence clinical management.N/A

    May include single-gene tests or focused panels when clinically indicated.

    Clarification of a clinical syndrome: Testing to identify a causative etiology for a phenotype with multiple potential genetic causes.N/A

    Panel testing may be appropriate when phenotype is nonspecific and multiple genes are implicated.

    Hereditary cancer evaluation: Germline testing to determine inherited cancer risk in asymptomatic individuals with appropriate family history or in affected individuals when results affect management or surveillance.meets guideline-based criteria

    Refer to NCCN and other guideline-based criteria as applicable; prior authorization/authorization tool criteria apply.

    Somatic tumor profiling: Therapeutic testing of tumor tissue or circulating tumor DNA to identify somatic variants that guide targeted therapy selection or subtype a cancer.N/A

    Per policy, per-component authorization is required for panels represented by multiple CPT codes; refer to coding grids.

    Clinical utility standardClinical utility requires that test results provide information used to formulate treatment or monitoring strategies that inform patient outcomes and impact clinical decisions.
    Insufficient evidence = NMNTests with extremely limited published data or insufficient evidence demonstrating clinical validity or utility are considered not medically necessary.
    Context-specific assessmentCoverage depends on clinical validity and clinical utility specific to the condition and clinical context; lack of utility for individual genes within a panel may affect coverage of the whole panel.
    Billing Rule

    Submission Route and Ordering‑Provider Responsibilities

    Requests for authorization of biomarker testing should be submitted via the BCBSRI online prior authorization tool (available to BCBSRI‑participating providers). If a test or CPT code is not found in the online tool, fax the prior authorization request to Utilization Management at (401) 272-8885. Laboratories are not permitted to obtain authorization on behalf of the ordering physician — only the ordering physician may initiate authorization, appeals, or provide necessary documentation.

    • Submission route: BCBSRI online prior authorization tool for participating providers; fax to Utilization Management (401) 272-8885 if not available online.
    • Panel testing submission: enter each individual CPT code separately into the online tool and process each component independently.
    • Provider action: only the ordering physician may handle authorizations/appeals; laboratories and their representatives must not submit or facilitate authorizations.
    Prior Authorization

    PCP Exemption (Fully‑Funded Commercial Products)

    Effective 2025-10-01, for Fully‑Funded Commercial Products only, prior authorization requests may not be needed when the requesting physician is a BCBSRI contracted Primary Care Provider credentialed in one of the following specialties: Internal Medicine; Pediatric Medicine; Family Practice; Obstetrics and Gynecology; Doctor of Osteopathic Medicine; NP (Nurse Practitioner)/PCP; PA (Physician Assistant). This exemption does not apply to Self‑Funded Commercial Products or Medicare Advantage Plans.

    • Exemption applies only to Fully‑Funded Commercial Products and only when the ordering provider is a BCBSRI‑contracted PCP in the listed specialties.
    • No step‑therapy is specified as part of this PCP exemption.
    • Prior authorization remains required for all other Commercial Products and Medicare Advantage Plans.
    Documentation Required

    Coding Grid and Coverage Reference

    Refer to the attached coding grids for Medicare Advantage Plans and Commercial Products for details on which HCPCS/PLA/MAAA and pathology/laboratory codes require prior authorization, which codes are covered when criteria are met, and which are not medically necessary or not covered. Use the grids to determine diagnosis code requirements and related policy references.

    • Coding grid requirement: see attached grids for HCPCS/PLA/MAAA, pathology/lab codes, and CPT code coverage indicators.
    • Provider action: consult the grids to confirm whether prior authorization is required, recommended, or not applicable for a given code and member plan.
    • Tests lacking demonstrated clinical utility are identified in the grids and may be flagged as Not Medically Necessary (NMN) or Not Covered.
    Denial Risk

    Prior Authorization, Benefit Verification, and Financial Liability

    For member‑specific benefit and eligibility determinations, contact the provider call center. If services are determined to be not medically necessary or non‑covered, do not bill the member unless the member has been informed in writing and has agreed in advance to assume financial responsibility.

    • Prior authorization / benefit verification: contact the provider call center for member‑specific benefit information before ordering tests.
    • Member financial liability: services determined NMN or non‑covered may result in denial and potential member liability if the member provided prior written consent to pay.
    • Unauthorized lab services: if a laboratory provides a service that has not been authorized, the service may be denied and financial liability may fall to the participating laboratory (not the member).
    PurposePerformed to detect biomarkers that may indicate normal or pathogenic processes or pharmacologic responses to interventions.
    Clinical utility
    DefinitionClinical utility means the test result provides information used in the formulation of a treatment or monitoring strategy that informs patient outcomes and impacts clinical decision-making.
    ActionabilityThe most appropriate test may include both immediately actionable information and some information not immediately usable for clinical decisions.
    Coverage implicationDemonstrated clinical utility is required for coverage; lack of utility can render a test not medically necessary.
    Panel
    DefinitionA genetic panel is a test that simultaneously evaluates multiple genes (e.g., via next-generation sequencing, massive parallel sequencing, or chromosomal microarray analysis).
    ExclusionThe panel definition excludes panels that report on gene expression profiling, which generally do not directly evaluate genetic variants.
    VariabilityPanel composition is not standardized and varies by laboratory; composition may change over time as new variants are added.
    Genetic testing
    DefinitionAnalysis of chromosomes, DNA, RNA, genes, or gene products to detect inherited (germline) or noninherited (somatic) genetic variants related to disease or health.
    ScopeEncompasses testing to identify both hereditary conditions and somatic changes relevant to diagnosis or treatment.
    MethodsMay include targeted gene tests, sequencing, and other molecular analyses depending on clinical indication.
    Carrier testing
    DefinitionA carrier has one abnormal allele for a disorder; carrier testing is used for family members, known carriers, or individuals from ethnic/racial groups with higher carrier rates.
    Clinical contextCarriers are typically unaffected for autosomal recessive or X-linked conditions; carrier testing informs reproductive risk assessment.
    IndicationsOffered to those with family members who have a genetic condition, those with identified carrier relatives, or members of high-risk populations.
    Germline variants
    DefinitionGermline variants are present in the DNA of every cell of the body from conception and include cells in the gonads; they can be transmitted to offspring.
    InheritanceBecause germline variants are present in gonadal cells, they may be passed to future generations.
    Clinical relevanceIdentification of germline variants is important for hereditary disease diagnosis and familial risk assessment.
    Somatic variants
    DefinitionSomatic variants are genetic changes acquired over time that are restricted to specific cells or cell populations and, if not in gonadal cells, are not passed to offspring.
    Clinical roleSomatic variants are commonly evaluated in tumor profiling to subtype cancers or to guide targeted therapies.
    TransmissionSomatic variants are generally not transmissible to offspring unless present in gonadal cells.
    Pharmacogenomics
    DefinitionPharmacogenomics studies how a person's genetic makeup affects their body's response to drugs.
    PurposeUsed to predict drug efficacy, dosing, or risk of adverse reactions based on genetic variation.
    Clinical applicationPharmacogenomic results can inform medication selection and management when evidence of clinical utility exists.
    References
    References overviewPolicy references include peer-reviewed studies, systematic reviews, and professional guidelines relevant to carrier screening and multigene panels (examples: Gross et al., Burke et al., ACMG/ACOG guidance, and NCCN guidelines).
    Selected citationsIncludes literature on carrier screening, clinical utility of expanded carrier screening, and multigene panel evaluations (see attached reference list entries).
    Guideline sourcesProfessional guideline sources cited include organizations such as ACMG and NCCN used to inform coverage decisions.

    Effective 2025-10-01, fully-funded Commercial Products may exempt BCBSRI-contracted PCPs from prior authorization for biomarker testing.

    2023-07-21Reference update

    NCCN guideline reference cited (accessed 2023-07-21) added to references supporting genetic/familial high-risk assessment guidance.